<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393287</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-A-RSD-2014-07</org_study_id>
    <nct_id>NCT02393287</nct_id>
  </id_info>
  <brief_title>Retroprospective Real Life Observatory of Eribulin</brief_title>
  <acronym>ReProLine</acronym>
  <official_title>Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observational Multicentric Retroprospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this observatory is to evaluate the effecacy of Eribulin in patients with
      metastatic breast cancer on a recent prescription period.

      Part of the data collection will be retrospective and the other part will be prospective for
      patients started treatment by Eribulin between November 2014 and September 2015. It will
      allow a better assessment on the safety profile of this drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately one third of patients treated for localized breast cancer will present a
      metastatic evolution and 5% of patients are metastatic immediately.

      At this stage, the malignancy is incurable with a median survival from 2 to 3 years.

      Metastatic breast cancer treatment is part of a multidisciplinary approach. These two
      objectives are to prolong survival and improve quality of life. At present, there is no
      standard after the first line of chemotherapy, with fe strategy studies Eribulin is now a new
      therapeutic option to consider. Many patients have benefited from this treatment option and
      it seems interesting to evaluate in real life the effecacy and tolerance of chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival is defined as the time between the first administration of Eribulin and death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival by subgroup</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival is defined as the time between the first administration of Eribulin and death from any cause in the following subgroups:
According to the administration line of Eribulin: administration in third line or more versus administration in first or second line or for locally advanced cancer,
in HER2 + population
in triple negative population
in the elderly (&gt; 70 years)
in the overweight population (BMI&gt; 30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival is defined as the time between the first administration of Eribulin and the first demonstrated progression by image</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response rate</measure>
    <time_frame>1 year</time_frame>
    <description>Treatment response rate will be assessed by:
the best response obtained between the first administration of treatment with Eribulin and demonstrated progression by image (according to RECIST 1.1 criteria) or clinical
the clinical benefit (number of complete responses, partial responses or persistent stabilities mare than 6 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment's tolerance</measure>
    <time_frame>1 year</time_frame>
    <description>The treatment's tolerance will be assessed by collecting adverse events ≥ grade 3 quoted according to NCI CTCAE v4.0 classification.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">753</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Reproline</arm_group_label>
    <description>this is an observational trial ; there is no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Eribulin (ReProLine)</intervention_name>
    <description>this is an observational trial ; there is no intervention</description>
    <arm_group_label>Reproline</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population includes all patients treated by Eribulin for breast cancer whose treatment
        has been starting between January 2014 and September 2015
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Patient with breast cancer, histologically proven, metastatic or locally advanced

          3. Patient treated by Eribulin between January and October 2014 (for the retrospective
             part) or between November 2014 and September 2015 (for the prospective part).

          4. Patient with at least an assessment of the response to Eribulin

        Exclusion Criteria:

          1. Presence of other neoplasia

          2. Man
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne PATSOURIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Bernard</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <zip>44802</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Saint Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

